SCHEMBL6653750

SCHEMBL6653750

CC(C)(C)OC(=O)NC(=N)N(OCCCOc1cc(Cl)cc(C(=O)OCc2ccccc2)c1)C(=O)OC(C)(C)C

nearest known ligand 0.37

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
F2 P00734 1/20 0.37
L3MBTL1 Q9Y468 5/20 0.35
SYK P43405 1/20 0.34
MAPT P10636 3/20 0.33
CTSL P07711 1/20 0.33
IDO1 P14902 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HPGD P15428 1/20 0.33
SLC6A2 P23975 1/20 0.33
SLC6A3 Q01959 1/20 0.33
KMT2A Q03164 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
CYP2C9 P11712 1/20 0.33
PTGER1 P34995 1/20 0.33
HIF1A Q16665 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.32
RAB9A P51151 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6653753 0.84 F2 (0.42) F2L3MBTL1MAPTALDH1A1HPGD
SCHEMBL6653752 0.78 F2 (0.40) F2L3MBTL1SYKMAPTSLC6A2
SCHEMBL6653749 0.78 F2 (0.40) F2L3MBTL1SYKMAPTSLC6A2
SCHEMBL3249068 0.76 SMN1; SMN2 (0.50) L3MBTL1SYKMAPTCTSLIDO1
SCHEMBL6749458 0.76 PTGER1 (0.41) L3MBTL1MAPTCYP2C9PTGER1
SCHEMBL6749687 0.75 CA12 (0.32)
SCHEMBL6653024 0.72 KMT2A (0.48) F2L3MBTL1MAPTALDH1A1HPGD
SCHEMBL6653550 0.72 KMT2A (0.50) F2L3MBTL1MAPTALDH1A1HPGD
SCHEMBL7310898 0.71 KMT2A (0.59) L3MBTL1MAPTALDH1A1HPGDSLC6A2
SCHEMBL6749182 0.70 F2 (0.54) F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1070049-B1 BENZAMIDE AND SULFONAMIDE SUBSTITUTED AMINOGUANIDINES AND ALKOXYGUANIDINES AS PROTEASE INHIBITORS DIMENSIONAL PHARM INC (US) 2004-06-30 EP disclosed
US-6344486-B1 ANTICOAGULANTS 3-DIMENSIONAL PHARMACEUTICALS, INC. 2002-02-05 US disclosed
US-6344466-B2 ANTITHROMBOTIC ACTIVITY, USE IN INHIBITING LOSS OF BLOOD PLATELETS, INHIBITING FORMATION OF BLOOD PLATELET AGGREGATES, INHIBITING FORMATION OF FIBRIN, ANTICOAGULANTS 3-DIMENSIONAL PHARMACEUTICALS INC. 2002-02-05 US disclosed
US-20010031870-A1 Benzamide and sulfonamide substitued aminoguanidines and alkoxyguanidines as protese inhibitors SOLL RICHARD M (US) 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010031870-A1 Benzamide and sulfonamide substitued aminoguanidines and alkoxyguanidines as protese inhibitors PLG, F9, TFPI F2 18/4885L3MBTL1 1362/4885SYK 947/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.